Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)
NCT00565266 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 210
Last updated 2018-07-02
Summary
Typically, people with asthma are initially prescribed a low dose of inhaled corticosteroid (ICS) medication to control asthma symptoms. If a low dose of ICS is ineffective at controlling symptoms, the addition of a second controller medication is recommended. This study will examine the effectiveness of the medication tiotropium bromide combined with a low dose of ICS at maintaining asthma control in people with moderately severe asthma.
Conditions
Interventions
- DRUG
-
tiotropium bromide
tiotropium bromide inhalation powder 18 mcg once daily
- DRUG
-
salmeterol xinafoate
salmeterol xinafoate inhalation powder 50 mcg twice daily
- DRUG
-
beclomethasone dipropionate
beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH -
Milton S. Hershey Medical Center
lead OTHER
Principal Investigators
-
Homer A. Boushey, MD · University of California, San Francisco
-
Richard J. Martin, MD · National Jewish Health
-
Elliot Israel, MD · Brigham and Women's Hospital
-
Stephen I. Wasserman, MD · University of California, San Diego
-
Mario Castro, MD · Washington University School of Medicine
-
Emily A. DiMango, MD · Columbia University
-
Stephen P. Peters, MD, PhD · Wake Forest University Health Sciences
-
Monica Kraft, MD · Duke University
-
William J. Calhoun, MD · University of Texas
-
Robert F. Lemanske, MD · University of Wisconsin, Madison
-
Reuben M. Cherniack, MD · National Jewish Health
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-05-31
- Primary Completion
- 2010-05-31
- Completion
- 2010-05-31
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma
NCT01634113 ·Status: COMPLETED ·Phase: PHASE2
-
Exacerbation Risk in Asthma
NCT05501639 ·Status: COMPLETED
-
A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma
NCT01383499 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma
NCT01122680 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma
NCT01277523 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Investigate the Effect of Inhaled Tiotropium Bromide on Neurokinin-A Induced Bronchoconstriction in Patients With Mild-to-moderate Asthma
NCT00557700 ·Status: COMPLETED ·Phase: PHASE2
-
Appropriate Inhaler Use of Tiotropium As Add-on Therapy in Symptomatic Asthma
NCT04696965 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma
NCT01257230 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Tiotropium Add-on Therapy in Patients With Asthma
NCT03964220 ·Status: COMPLETED
-
Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg
NCT00350207 ·Status: COMPLETED ·Phase: PHASE2
-
Steroids In Eosinophil Negative Asthma
NCT02066298 ·Status: COMPLETED ·Phase: PHASE3
-
Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications
NCT00557180 ·Status: COMPLETED
-
A Methodology Study To Look At Genes In Lung Cells And Tissue From Asthmatic Patients
NCT00331292 ·Status: TERMINATED
-
Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma
NCT01634139 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma
NCT02513160 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma
NCT01634152 ·Status: COMPLETED ·Phase: PHASE3
-
TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA
NCT02676076 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma
NCT00116103 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM
NCT00652392 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma
NCT00862264 ·Status: COMPLETED ·Phase: PHASE3
-
Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma
NCT00189722 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma
NCT00476268 ·Status: COMPLETED ·Phase: PHASE3
-
A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma
NCT02680561 ·Status: COMPLETED ·Phase: PHASE1
-
A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma
NCT00452699 ·Status: COMPLETED ·Phase: PHASE4
-
Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home
NCT01783132 ·Status: TERMINATED ·Phase: NA